Class IITerminatedD-1836-2019
Drug recall · August 28, 2019
Bexarotene Capsules recall
Why: Failed Dissolution Specifications
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Bexarotene Capsules, 75 mg, 100 capsules per bottle, Rx Only, Manufactured for: Upsher-Smith Laboratories, LLC, Maple Grove, MN 55369. NDC: 0832-0285-00
- Lots / codes
Lot: A2610. exp 3/2020
- Quantity
- 166 bottles
- Company
- Upsher Smith Laboratories, Inc., Maple Grove, MN
- Distribution
- KY, OH, NJ, LA
- Initiated
- July 29, 2019 · Voluntary: Firm initiated
- Classified
- August 19, 2019
- Reported
- August 28, 2019
- Ended
- August 25, 2022
- How notified
- Telephone
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bexarotene
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.